



0360

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Michel Pairet et al ) Art Unit: to be assigned  
Serial No. : 10/086,145 ) Examiner: to be assigned  
Filed : October 19, 2001 ) Docket No.: 1/1174  
For : Pharmaceutical Compositions Based on Anticholinergics and  
Corticosteroids

Assistant Commissioner for Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and

☒ 1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

☒ The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

The references cited on the enclosed Form 1449A/PTO are not conceded to be prior art.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Timothy X. Witkowski  
Attorney for Applicant(s)  
Reg. No. 40,232


Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT 06877  
Tel.: (203) 798-4310  
Docket No.: 1/1174

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, DC 20231

on April 1, 2001

By: Timothy X. Witkowski  
Reg. No. 40,232



Substitute for form 1449A/PTO

**Complete if Known**

(use as many sheets as necessary)

Sheet

1

of

1

Application Number

10/086.145

Filing Date

October 19, 2001

**First Named Inventor**

**Michel Pairet**

Art Unit

to be assigned

Examiner Name

to be assigned

Attorney Docket Number

1/1174

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		WO-01/78736-A1	10/25/2001	Galxo Group Limited		
		WO-01/78739-A1	10/25/2001	Glaxo Group Limited		
		WO-01/78741-A1	10/25/2001	Glaxo Group Limited		
		WO-01/78743-A1	10/25/2001	Glaxo Group Limited		

Examiner  
Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Business Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.